Featured News

With tech and other industries actively aligning with the incoming administration, how are healthcare companies navigating the evolving political landscape — and how did that...

By day I work with study sponsors on communication around clinical trials to accelerate recruitment and increase retention. Lately, in off hours, I find myself...

This report was last updated Jan. 2, 2025. The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound...

Do you remember everything you ever learned? If the answer is “no,” do you expect your doctor to? With all the information crammed into our...

As we approach the start of a new year, we're thinking about what trends will be impacting the biotech industry in 2025. And how can...

When we used RCIS Workspace, our AI-powered insights platform, for the first time, we were struck by its potential to fundamentally change our approach to...

Today’s biopharma companies are pioneers, developing innovative therapies, new approaches to personalized medicine, and cutting-edge technologies to address healthcare’s most challenging issues.  However, scientific breakthroughs...

Confession: As a creative, I don’t trust AI. Creativity isn’t linear or predictable. AI can’t feel. It can’t understand what makes someone tick. So, can...

GLP-1 receptor agonists, originally developed for managing type 2 diabetes, have rapidly emerged as highly effective treatment options for obesity. Medications such as semaglutide (branded...